Advent of Oncology Monoclonal Antibody Biosimilars – A European
Perspective will feature world-renowned oncologists
CRANBURY, N.J.–(BUSINESS WIRE)–Physicians’ Education Resource®, LLC (PER®), the
leading resource for oncology and hematology continuing medical
education, will produce its first livestream European webcast, “Advent
of Oncology Monoclonal Antibody Biosimilars – A European Perspective” on
October 27, 2017, at 2:00 p.m. GMT.
The webinar will be co-chaired by Hope S. Rugo, MD, professor of
medicine, director, Breast Oncology and Clinical Trials Education,
University of California San Francisco, Helen Diller Family
Comprehensive Cancer Center, and Giuseppe Curigliano, MD, PhD,
chair, Division of Early Drug Development at the European Institute of
Oncology in Milan, Italy.
“We are very excited to launch this new virtual webcast meeting to a
European audience. We are going to film it in our own state-of-the-art
studio that allows us to broadcast live, in real-time, to Europe. We
worked with Dr. Hope Rugo to carefully select faculty that are experts
in the space and can share a collaborative opinion on the state of
biosimilars and its impact on treating cancer in Europe,” said Phil
Talamo, president of PER®.
There will be discussions throughout the webinar about the 20
biosimilars approved by the European Medicines Agency. The webinar is
designed to educate European pharmacists and physicians about the
advantages of biosimilars in terms of their potential to reduce the
acquisition cost of cancer drugs, thereby increasing affordability and
patient access. Focus will be on the importance of analytical studies to
the development and regulatory approval of biosimilars, the concepts of
immunogenicity and extrapolation of indications based on evaluation of
the totality of the evidence and mechanism of action rationale, and the
potential risks related the suboptimal use of biosimilars and strategies.
For registration and more information, visit www.gotoper.com/go/eurobio17pr.
Since 1995, PER® has been the educational resource of choice
for live and online activities focusing on oncology and hematology. PER®
provides high-quality, evidence-based activities featuring leading
national and international faculty, with a focus on practice-changing
advances and standards of care in treatment and disease management.
Activities also include topics on emerging strategies currently under
investigation, supportive care, diagnosis and staging, prevention,
screening and early detection, and practice management. With the rapid
advances occurring in the field of oncology, understanding how to use
molecular data to diagnose and stage patients, selecting the most
appropriate candidates for novel therapeutic agents, individualizing
treatment based on tumor type and referring patients to clinical trials
will continue to ensure the highest level of patient care is provided.
PER® serves the oncology health care community, including
physicians, fellows, advanced practice nurses, nurses, physician
assistants, pharmacists and researchers. PER® is part of the
Cranbury, N.J.-based Michael J. Hennessy Associates, Inc. family of
businesses. Learn more at http://www.gotoper.com